Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: An overview of long-term randomized controlled trials

Archives of Internal Medicine

Volumn 166, Issue 7, 2006, Pages 787-796

  Danchin, Nicolas ^a   Cucherat, Michel ^c   Thuillez, Christian ^d   Durand, Eric ^a   Kadri, Zena ^a   Steg, Philippe G ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b BICHAT HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LOSARTAN POTASSIUM; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; RAMIPRIL; SIMVASTATIN; SPIRAPRIL; TRANDOLAPRIL;

CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DATA ANALYSIS; DIABETES MELLITUS; EMBASE; FOLLOW UP; HEART ARREST; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INTERMITTENT CLAUDICATION; MEDLINE; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; RESUSCITATION; REVIEW; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; FEMALE; HOSPITALIZATION; HUMANS; INDOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33645740812     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.7.787     Document Type: Review

References (63)

1. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data of individual patients. Lancet. 2000;355:1575-1581.
2. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115:473-479.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. [published correction appear in N Engl J Med. 2000;342:748 and 2000; 242:1376]. N Engl J Med. 2000;342:145-153.
4. Fox KM. European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease investigators. Efficacy of perindopril on reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
5. Braunwald E, Domanski MJ, Fowler SE, et al; PEACE trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71-86.
7. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
9. Snow V, Barry P, Fihn SD, et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;141:562-567.
10. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular. Am J Cardiol. 2001;87:1058-1063.
11. Nissen SE, Tuzcu EM, Libby P, et al; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study; a randomized controlled trial. JAMA. 2004;292:2217-2226.
12. Teo KK, Burton JR, Butler CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748-1754.
13. MacMahon S, Sharpe N, Gamble G, et al; PART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000;36:438-443.
14. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000;35:881-888.
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses. Lancet. 1999;354:1896-1900.
16. Altman DG, Schulz KF. Statistics notes: concealing treatment allocation in randomised trials. BMJ. 2001;323:446-447.
17. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42-46.
18. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060.
19. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol. 1994;140:290-296.
20. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. EasyMA: a program for the meta-analysis of clinical trials. Comput Meth Programs Biomed. 1997;53:187-190.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
22. Lees RS, Pitt B, Chan RC, et al. Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial. Am J Cardiol. 1996;78:1011-1016.
23. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard AC. The Quinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther. 1993;7:273-282.
24. The HOPE Study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 1996;12:127-137.
25. Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ; SCAT Investigators. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Can J Cardiol. 1997;13:591-599.
26. Gomma AH, Fox KM. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther. 2001;15:169-179.
27. Pfeffer MA, Domanski M, Rosenberg Y, et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol. 1998;82:25H-30H.
28. Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease. N Engl J Med. 2005;352:937-938.
29. Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). Am J Cardiol. 2001;87:542-546.
30. Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
31. Faxon DP; Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. Effect of high-dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995;2:362-369.
32. Desmet W, Vrolix M, De Scheerder I, Van Lierde J, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation. 1994;89:385-392.
33. Meurice T, Bauters C, Hermant X, et al. Effects of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double blind, placebo-controlled trial. Lancet. 2001;357:1321-1324.
34. Kaul U, Chandra S, Bahl VK, Sharma S, Wasir HS. Enalapril for prevention of restenosis after coronary angioplasty. Indian Heart J. 1993;45:469-473.
35. Yamabe T, Imazu M, Yamaoto H, et al. Effect of cilazapril in vascular restenosis after percutaneous transluminal coronary angioplasty. Coronary Artery Dis. 1995;6:573-579.
36. Otsuka M, Yamamoto H, Okimoto T, et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J. 2004;147:662-668.
37. Sadamatsu K, Shimokawa H, Tashiro H, Yamamoto K. Long-term treatment with enalapril reduces plasma concentrations of macrophage colony stimulating factor in patients with coronary artery disease. Heart. 2001;86:457-458.
38. Di Mario C, Strikwerda S, Gil R, Azar A, Rames A, Serruys PW. Long-term changes in the response of conductance and resistance coronary vessels to endothelium-dependent and independent vasodilators: a double-blind placebo-controlled study of the effect of a 6-month treatment with cilazapril. Ital Heart J. 2000;1:674-683.
39. Mancini GB, Henry GC, Macaya C, et al. the TREND (Trial on Reversing Endothelial Dysfunction) Study. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;94:258-265.
40. Esper RJ, Machado R, Vilarino J, et al. Endothelium-dependent resonses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. Am Heart J. 2000;140:684-689.
41. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium-channel blockade on flow-mediated vasodilatin in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35:60-66.
42. Toyofyuku M, Imazu M, Sumii K, et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin-converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis. 2002;160:339-344.
43. Koh KK, Son JW, Ahn JY, et al. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atherosclerosis. 2004;177:147-153.
44. Thurmann P, Rietbrock N. Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease. Blood Press. 1994;2(suppl):73-76.
45. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol. 1994;23:652-657.
46. van den Heuvel AF, Dunselman PH, Kingma T, et al. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta-blockage. J Am Coll Cardiol. 2001;37:470-474.
47. Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol. 2003;42:2049-2059.
48. Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002;88:100-107.
49. Dhawan S, Soni D, Chandra N, Dviwedi S, Agarwal A, Puri VK. Use of captopril as an isolated agent for the management of stable angina pectoris: a double-blind randomised trial. Indian Heart J. 1992;85:2004-2013.
50. Thurmann P, Odenthal HJ, Rietbrock N. Converting enzyme inhibition in coronary artery disease: a randomized, placebo-controlled trial with benazepril. J Cardiovasc Pharmacol. 1991;17:718-723.
51. Bartels GL, van den Heuvel FM, van Veldhuisen DJ, van der Ent M, Remme WJ. Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol. 1999;83:332-336.
52. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Effects of enalapril during continuous nitrate therapy: analysis of diameter of coronary arteries and platelet cyclic guanosine monophosphate. Am Heart J. 1997;134:614-621.
53. Metelitsa VI, Martsevich SY, Kozyreva MP, Slastnikova ID. Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris. Am J Cardiol. 1992;69:291-296.
54. Klein WW, Khurmi NS, Eber B, Dusleag J. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. J Am Coll Cardiol. 1990;16:948-956.
55. Unterberg C, Buchwald A, Vogt A, Wiegand V. Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease [in German]. Med Klin (Munich). 1990;85:78-81.
56. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849-857.
57. Raasch W, Dendorfer A, Ball B, Dominiak P. The lipophilic properties of angiotensin-I converting enzyme inhibitors do not influence their diffusion through cultured endothelium. Jpn J Pharmacol. 1999;81:346-352.
58. Myers MG; Perindopril Multicentre Dose-Response Study Group. A dose-response study of perindopril in hypertension effects on blood pressure 6 and 24 h after dosing. Can J Cardiol. 1996;12:1191-1196.
59. Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003;25:713-775.
60. Baudin B, Drouet L. In vitro interactions between ramiprilat and angiotensin I-converting enzyme in endothelial cells. J Cardiovasc Pharmacol. 1989;14(suppl 4):S37-S42.
61. Sennesael J, Ali A, Sweny P, et al. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. Br J Clin Pharmacol. 1992;33:93-99.
62. Chevillard C, Journey S, Bree F, et al. Compared properties of trandolapril, enalapril, and their diametabolites. J Cardiovasc Pharmacol. 1994;23(suppl 4):S11-S15.
63. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on therosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.